論文

査読有り 国際誌
2017年7月1日

Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.

Cancer letters
  • Koichiro Takayama
  • ,
  • Takamitsu Inoue
  • ,
  • Shintaro Narita
  • ,
  • Shinya Maita
  • ,
  • Mingguo Huang
  • ,
  • Kazuyuki Numakura
  • ,
  • Hiroshi Tsuruta
  • ,
  • Mitsuru Saito
  • ,
  • Atsushi Maeno
  • ,
  • Shigeru Satoh
  • ,
  • Norihiko Tsuchiya
  • ,
  • Tomonori Habuchi

397
開始ページ
103
終了ページ
110
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.canlet.2017.03.034

Androgen deprivation therapy (ADT) for patients with metastatic or locally advanced prostate cancer reduces bone mineral density by stimulating receptor activator of nuclear factor kappa-B (RANK) signaling in osteoclasts. The involvement of the RANK/RANKL signaling in ADT-induced acceleration of bone metastasis in castration-insensitive prostate cancer was examined in a murine model using osteoprotegerin (OPG). Male Balb/c nude mice were divided into three groups: the non-castration, castration, and castration + OPG groups. PC-3M-luc-C6 was injected into the left ventricle of the mice. Recombinant OPG was injected intravenously twice weekly in the castration + OPG group. In-vivo imaging system (IVIS®) determined that the prevalence and photon counts of bone metastasis in the castration group were significantly higher than that in the non-castration and castration + OPG groups. The mean number of RANKL-positive osteoblasts and the mean serum RANKL level in the castration group were significantly higher than those in the non-castration group. RANKL-enhanced activation of osteoclasts was attenuated in the castration + OPG group. These results suggest that the mechanisms of RANK/RANKL signaling are involved in the ADT-induced acceleration of bone metastasis in castration-insensitive prostate cancer.

リンク情報
DOI
https://doi.org/10.1016/j.canlet.2017.03.034
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28373003

エクスポート
BibTeX RIS